AGIO vs VERX: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
VERX is the larger of the two ($2.83B market cap): the incumbent the market prices for continued execution (16.75x forward earnings, beta 0.75). AGIO is the smaller challenger ($1.69B), still expected to post a loss next year: more room to run, but more to prove. If you believe in growth, AGIO fits: analysts expect its revenue to rise 88% next year, against 10% for VERX. If you believe in profit, VERX fits: it is expected to make money next year (16.75x forward earnings), while AGIO is still expected to post a loss.
AGIO vs VERX: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | AGIO | VERX | What it tells you |
|---|---|---|---|
| Market cap | $1.69B | $2.83B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | -9.14 | 16.75 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.62 | 0.75 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 25% of range | 68% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 1.73 | 15.05 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how AGIO and VERX affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AGIO and VERX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AGIO and VERX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Agios Pharmaceuticals (AGIO) do?
Agios Pharmaceuticals develops medicines for rare hematologic (blood) diseases. Its lead product, mitapivat, is an oral pyruvate kinase (PK) activator sold as PYRUKYND for PK deficiency and, following a 2026 approval, as AQVESME for thalassemia (US launch January 2026; PYRUKYND was also approved for thalassemia in the EU in late May 2026). The company is pursuing accelerated approval of mitapivat in sickle cell disease. The FDA granted Priority Review to that application in 2026 with a decision expected by November 1, 2026, but in late October it extended the goal date by three months to February 1, 2027, after asking for more information on whether a REMS (a formal risk-management program) is needed and classifying Agios' response as a major amendment. Agios previously sold its oncology business to Servier in 2021, which left it focused purely on hematology and entitled to a royalty on US net sales of Servier's brain-cancer drug Voranigo (vorasidenib).
What does Vertex (VERX) do?
Vertex, Inc. (NASDAQ: VERX) is a global provider of indirect tax software, content, and services that help large and mid-size enterprises calculate, collect, and report taxes such as sales and consumer use tax, value added tax (VAT), and payroll-related indirect taxes. Its core O Series platform plugs into the ERP, e-commerce, procurement, and billing systems that big companies already run (SAP, Oracle, Workday, Salesforce and others) and applies a continuously updated database of tax rules across thousands of jurisdictions so that the correct tax is applied on every transaction. Founded in 1978 and public since 2020, Vertex serves roughly 4,900 direct customers, many of them large multinationals, and earns the bulk of its revenue from recurring software subscriptions plus related services, with annual recurring revenue per customer of about $137,867 as of late 2025.
AGIO vs VERX: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- AGIO drivers: Mitapivat franchise expansion; Sickle cell decision, now February 2027.
- VERX drivers: Recurring, mission-critical tax compliance; Cloud migration and higher-value expansion.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Agios remains deeply unprofitable, reporting a quarterly GAAP loss of $1.09 per share in Q3 2026 and about $373 million of net losses over the trailing year, while product revenue is still modest at about $141 million over the same period. For VERX, vertex shares fell sharply from late 2025 into 2026, driven by deteriorating key performance indicators, extended sales cycles, and reduced growth and margin expectations.
AGIO or VERX: which should you pick?
If the story you believe is AGIO's (Mitapivat franchise expansion), AGIO is the more direct way to own it; if it is VERX's (Recurring, mission-critical tax compliance), VERX is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AGIO and VERX guides.
AGIO vs VERX: the full fundamentals
AGIO. Agios trades at about 12 times trailing revenue, down from about 19 times in October as sales grew and the stock fell on the FDA extension, and the valuation still rests on the sickle cell opportunity rather than current earnings. Analysts expect revenue of about $185 million in 2026 and $349 million in 2027, with losses narrowing to about -$3.00 per share in 2027. The nine covering analysts carry a buy rating and a mean target of about $46 (BofA trimmed its target to $48 from $50 after the quarter), well above the price.
VERX. As of November 20, 2026, Vertex traded at a market cap of about $2.8 billion, roughly 3.5 times trailing revenue and about 17 times 2027 earnings estimates, up from about 2.7 times sales and 13 times forward earnings in mid-October after the Q3 beat lifted the shares. There is no meaningful trailing P/E because GAAP results swung to a loss in Q3, so the forward multiple and adjusted EBITDA (guided to about $218-220 million for 2026) are the more useful gauges while restructuring savings ramp. The 13 analysts in Yahoo's count have a mean target near $21.
Headline figures (approximate, November 2026): AGIO shows revenue (ttm) ~$141M, q3 2026 revenue ~$55.4M (vs ~$12.9M a year earlier), ahead of ~$52M expected, q3 2026 eps ~-$1.09 vs ~-$1.23 expected, net loss (ttm) ~-$373M; free cash flow ~-$264M; VERX shows market cap ~$2.8 billion, revenue (ttm) ~$809 million, revenue growth (q3 2026, yoy) ~11%, q3 2026 revenue ~$213 million (adj. EPS $0.26 vs $0.22 est.).
The bottom line: AGIO vs VERX
AGIO and VERX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined AGIO and VERX exposure against your real portfolio. It is not an investment adviser.
Wondering how AGIO or VERX fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Agios Pharmaceuticals
Ask Walnut's AI anything about AGIO and see how it fits what you own.
FAQ
What is the difference between AGIO and VERX?
+
Agios Pharmaceuticals develops medicines for rare hematologic (blood) diseases. Vertex, Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is AGIO or VERX the better stock?
+
Neither is universally better. VERX is the larger incumbent; AGIO is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, AGIO or VERX?
+
A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both AGIO and VERX?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of AGIO vs VERX?
+
AGIO: Agios remains deeply unprofitable, reporting a quarterly GAAP loss of $1.09 per share in Q3 2026 and about $373 million of net losses over the trailing year, while product revenue is still modest at about $141 million over the same period. The business now depends almost entirely on a single molecule, so a negative trial or regulatory setback is materially damaging; tebapivat's discontinuation in both MDS and sickle cell in 2026 removed the main backup. The sickle cell decision, pushed to February 1, 2027, is binary, could come with a REMS that limits uptake, and accelerated approval would require a confirmatory trial that could still fail. Sickle cell and thalassemia are competitive markets with gene therapies, Novo Nordisk's etavopivat and other novel agents. Ongoing R&D and commercial spending will continue to burn cash, and while the balance sheet is solid today, sustained losses without pipeline success would eventually pressure it. VERX: Vertex shares fell sharply from late 2025 into 2026, driven by deteriorating key performance indicators, extended sales cycles, and reduced growth and margin expectations. They have rebounded about 29% over the three months to November 20, 2026 after a Q3 beat, but remain about 11% lower over one year, so sentiment can swing quickly in either direction. A CEO transition adds leadership and execution uncertainty at a moment when the company is also restructuring, and a botched reset could pressure both revenue and morale. Growth has settled around 10% from higher prior levels, and if enterprise buyers keep delaying decisions, subscription growth could slow further; management also expects net revenue retention to slip about a point in Q4 after losing a payroll-tax OEM partner, and SAP's extended 2027 migration deadline may push some demand later. Competition is intense from larger and well-funded rivals (including Avalara, Thomson Reuters ONESOURCE, Sovos, and Wolters Kluwer), which can pressure pricing and win rates. GAAP profitability is weak relative to adjusted EBITDA (a trailing net loss of about $47 million, including a Q3 2026 GAAP loss of about $47 million, and an operating margin near 3%) because of stock-based compensation, amortization and other charges, and debt of about $350 million exceeds cash of about $218 million. Several plaintiff law firms have publicized investigations following the stock decline, which, while common after large drops, add headline and potential litigation noise.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell AGIO or VERX; figures are approximate and dated (as of November 2026). Verify current data before investing.